Cell News and Research

RSS

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation. According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation. Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

10 Nov 2009

Trinity Health to install Elsevier's online CDS solutions

Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.

10 Nov 2009

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics.

10 Nov 2009

Researchers discover cells that protect the respiratory tract from developing an allergic response

According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.

10 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

10 Nov 2009

Activating TAp63 protein, a viable anti-cancer strategy

Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

10 Nov 2009

Scientists find way to splice cell networks down to their genesis

On Noah's Ark animals came in twos: male and female. In human bodies trillions of cells are coupled, too, and so are the molecules from which they are composed. Yet these don't come in twos, they are regrouped into indistinguishable clusters. Because these complex cell networks are the backbone of life - and illness - scientists have long searched for ways to splice cell clusters down to their original pairs.

10 Nov 2009

Beta-Pro helps meet growing demand for human pancreatic islets

Beta-Pro LLC, a biotechnology firm that provides diabetes researchers with custom cellular and consulting services, has entered a new phase of growth as it bridges the widening gap between an inconsistent, low quality supply of human pancreatic islets and skyrocketing demand.

10 Nov 2009

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage.

10 Nov 2009

Teenage women who are obese at higher risk to develop MS as adults

Teenage women who are obese may be more than twice as likely to develop multiple sclerosis (MS) as adults compared to female teens who are not obese, according to a study published in the November 10, 2009, print issue of Neurology-, the medical journal of the American Academy of Neurology.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

Harvest Technologies Corp. announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S. and one site in India using the company's Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI) has completed enrollment. Mark D. Iafrati, M.D. Chief of Vascular Surgery at Tufts Medical Center in Boston, directed the study.

10 Nov 2009

Celling Technologies and SpineSmith team up to research adipose tissue derived stem cell applications

Celling Technologies, a subsidiary of SpineSmith Partners, is collaborating with Tissue Genesis, Inc. to research potential applications for adipose tissue derived adult stem cells. SpineSmith acquired the global rights in spine for Tissue Genesis' adipose (fat) tissue derived stem cell technology in November of 2007.

10 Nov 2009

New technique to identify patients more likely to survive advanced melanoma

Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Now it may be possible to identify which patients are more likely to survive by analyzing the activity of hundreds of genes involved in the immune response and gene proliferation, according to researchers at NYU Langone Medical Center.

10 Nov 2009

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL).

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

Cell News and Research

BioVex completes $70M financing to complete OncoVEX Phase III study

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Trinity Health to install Elsevier's online CDS solutions

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Researchers discover cells that protect the respiratory tract from developing an allergic response

Study suggests a new improved treatment option for children with Hurler's syndrome

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

Activating TAp63 protein, a viable anti-cancer strategy

Scientists find way to splice cell networks down to their genesis

Beta-Pro helps meet growing demand for human pancreatic islets

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

Teenage women who are obese at higher risk to develop MS as adults

EpiCept announces third quarter 2009 financial results

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

Celling Technologies and SpineSmith team up to research adipose tissue derived stem cell applications

New technique to identify patients more likely to survive advanced melanoma

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News